This inventor holds 1 USPTO granted patent. Top assignee: Temple University. Active years: 2024.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2024
Title: Jumpei Yamazaki: Innovator in Acute Myeloid Leukemia Research
Introduction
Jumpei Yamazaki is a notable inventor based in Philadelphia, PA. He has made significant contributions to the field of medical research, particularly in the area of acute myeloid leukemia (AML). His work focuses on identifying biomarkers that can lead to more effective treatments for this challenging disease.
Latest Patents
Yamazaki holds a patent titled "Hypomethylation of TET2 target genes for identifying a curable subgroup of acute myeloid leukemia." This invention provides AML-specific methylation biomarkers, including SP140, MCCC1, EHMT1, and MTSS1. These biomarkers are differentially methylated specifically in AML, offering potential pathways for targeted therapies.
Career Highlights
Yamazaki is affiliated with Temple University, where he conducts his research. His work has garnered attention for its innovative approach to understanding the genetic factors involved in AML. With a focus on developing practical applications for his findings, he aims to improve patient outcomes in the field of oncology.
Collaborations
Yamazaki collaborates with Jean-Pierre J Issa, a prominent figure in cancer research. Their partnership enhances the depth and impact of their work, contributing to advancements in the understanding of leukemia.
Conclusion
Jumpei Yamazaki's contributions to the field of acute myeloid leukemia research exemplify the importance of innovation in medicine. His patented work on methylation biomarkers represents a significant step forward in identifying curable subgroups of this disease.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile